Epitalon
Longevity (pineal peptide)
Status & caution. Not FDA-approved. Among the 12 peptides removed from Category 2 in April 2026 and scheduled for PCAC review on 24 July 2026. Telomerase/longevity claims rest largely on a small body of older Russian research; extraordinary claims here lack extraordinary evidence.
At a glance
Indications & what it's studied for
Marketed for longevity, sleep, and telomere/telomerase support; proposed to regulate melatonin and circadian rhythm.
Contraindications & cautions
No established human contraindications; theoretical caution around telomerase activation and cancer biology.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community use reports short cycles of small subcutaneous doses; unvalidated.
Routes of administration
Subcutaneous injection.
Don't combine with
No characterised interactions documented.
Reported to stack with
Grouped with other 'longevity' peptides (MOTS-c, thymosin α-1) in community protocols.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Older Russian studies report effects on melatonin and lifespan in animals/small cohorts; independent replication is limited.
Before acting on anything here, see Safety & the grey market and how to read a COA.